BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liu E, Paulson S, Gulati A, Freudman J, Grosh W, Kafer S, Wickremesinghe PC, Salem RR, Bodei L. Assessment of NETest Clinical Utility in a U.S. Registry-Based Study. Oncologist 2019;24:783-90. [PMID: 30158287 DOI: 10.1634/theoncologist.2017-0623] [Cited by in Crossref: 35] [Cited by in F6Publishing: 41] [Article Influence: 8.8] [Reference Citation Analysis]
Number Citing Articles
1 Chiapponi C, Bruns CJ. Moderne molekulare und bildgebende Diagnostik bei neuroendokrinen Neoplasien des Pankreas. best practice onkologie 2022. [DOI: 10.1007/s11654-022-00451-y] [Reference Citation Analysis]
2 Komarnicki P, Musiałkiewicz J, Stańska A, Maciejewski A, Gut P, Mastorakos G, Ruchała M. Circulating Neuroendocrine Tumor Biomarkers: Past, Present and Future. JCM 2022;11:5542. [DOI: 10.3390/jcm11195542] [Reference Citation Analysis]
3 Chiapponi C, Bruns CJ. Moderne molekulare und bildgebende Diagnostik bei neuroendokrinen Neoplasien des Pankreas. Chirurgie 2022;93:731-738. [DOI: 10.1007/s00104-022-01645-4] [Reference Citation Analysis]
4 Kaliszewski K, Ludwig M, Greniuk M, Mikuła A, Zagórski K, Rudnicki J. Advances in the Diagnosis and Therapeutic Management of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs). Cancers (Basel) 2022;14:2028. [PMID: 35454934 DOI: 10.3390/cancers14082028] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 Fang JM, Li J, Shi J. An update on the diagnosis of gastroenteropancreatic neuroendocrine neoplasms. World J Gastroenterol 2022; 28(10): 1009-1023 [DOI: 10.3748/wjg.v28.i10.1009] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
6 Lee L, Ramos-Alvarez I, Jensen RT. Predictive Factors for Resistant Disease with Medical/Radiologic/Liver-Directed Anti-Tumor Treatments in Patients with Advanced Pancreatic Neuroendocrine Neoplasms: Recent Advances and Controversies. Cancers (Basel) 2022;14:1250. [PMID: 35267558 DOI: 10.3390/cancers14051250] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
7 Takayanagi D, Cho H, Machida E, Kawamura A, Takashima A, Wada S, Tsunoda T, Kohno T, Shiraishi K. Update on Epidemiology, Diagnosis, and Biomarkers in Gastroenteropancreatic Neuroendocrine Neoplasms. Cancers (Basel) 2022;14:1119. [PMID: 35267427 DOI: 10.3390/cancers14051119] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
8 Bodei L, Jayaprakasam VS, Kidd M, Gilardi L, Volterrani D, Paganelli G, Grana CM, Modlin IM. Neuroendocrine Tumors: Therapy with Radiolabeled Peptides. Nuclear Oncology 2022. [DOI: 10.1007/978-3-319-26067-9_50-3] [Reference Citation Analysis]
9 Bodei L, Jayaprakasam VS, Kidd M, Gilardi L, Volterrani D, Paganelli G, Grana CM, Modlin IM. Neuroendocrine Tumors: Therapy with Radiolabeled Peptides. Nuclear Oncology 2022. [DOI: 10.1007/978-3-319-26067-9_50-2] [Reference Citation Analysis]
10 Bodei L, Jayaprakasam VS, Kidd M, Gilardi L, Volterrani D, Paganelli G, Grana CM, Modlin IM. Neuroendocrine Tumors: Therapy with Radiolabeled Peptides. Nuclear Oncology 2022. [DOI: 10.1007/978-3-031-05494-5_50] [Reference Citation Analysis]
11 Ciobanu OA, Martin S, Fica S. Perspectives on the diagnostic, predictive and prognostic markers of neuroendocrine neoplasms (Review). Exp Ther Med 2021;22:1479. [PMID: 34765020 DOI: 10.3892/etm.2021.10914] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
12 Rinke A, Auernhammer CJ, Bodei L, Kidd M, Krug S, Lawlor R, Marinoni I, Perren A, Scarpa A, Sorbye H, Pavel ME, Weber MM, Modlin I, Gress TM. Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalised medicine? Gut 2021;70:1768-81. [PMID: 33692095 DOI: 10.1136/gutjnl-2020-321300] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
13 Modlin IM, Kidd M, Falconi M, Filosso PL, Frilling A, Malczewska A, Toumpanakis C, Valk G, Pacak K, Bodei L, Öberg KE. A multigenomic liquid biopsy biomarker for neuroendocrine tumor disease outperforms CgA and has surgical and clinical utility. Ann Oncol 2021:S0923-7534(21)03975-2. [PMID: 34390828 DOI: 10.1016/j.annonc.2021.08.1746] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
14 Modlin IM, Kidd M, Frilling A, Falconi M, Filosso PL, Malczewska A, Kitz A. Molecular Genomic Assessment Using a Blood-based mRNA Signature (NETest) is Cost-effective and Predicts Neuroendocrine Tumor Recurrence With 94% Accuracy. Ann Surg 2021;274:481-90. [PMID: 34183517 DOI: 10.1097/SLA.0000000000005026] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
15 Filosso PL, Öberg K, Malczewska A, Lewczuk A, Roffinella M, Aslanian H, Bodei L. Molecular identification of bronchopulmonary neuroendocrine tumours and neuroendocrine genotype in lung neoplasia using the NETest liquid biopsy. Eur J Cardiothorac Surg 2020;57:1195-202. [PMID: 32047924 DOI: 10.1093/ejcts/ezaa018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
16 Modlin IM, Kidd M, Bodei L, Malczewska A, Kitz A, Oberg K. Circulating biomarkers of gastroenteropancreatic and lung neuroendocrine neoplasms: “The times they are a changin”. Current Opinion in Endocrine and Metabolic Research 2021;18:243-253. [DOI: 10.1016/j.coemr.2021.03.017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Roll W, Weckesser M, Seifert R, Bodei L, Rahbar K. Imaging and liquid biopsy in the prediction and evaluation of response to PRRT in neuroendocrine tumors: implications for patient management. Eur J Nucl Med Mol Imaging 2021. [PMID: 33903926 DOI: 10.1007/s00259-021-05359-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
18 Effraimidis G, Knigge U, Rossing M, Oturai P, Rasmussen ÅK, Feldt-Rasmussen U. Multiple endocrine neoplasia type 1 (MEN-1) and neuroendocrine neoplasms (NENs). Semin Cancer Biol 2021:S1044-579X(21)00112-7. [PMID: 33905872 DOI: 10.1016/j.semcancer.2021.04.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
19 Frilling A, Clift AK, Frampton AE, Bomanji J, Kaemmerer D, Al-Nahhas A, Alsafi A, Kidd M, Modlin IM, Hoersch D, Baum RP. A combination of surgery, theranostics, and liquid biopsy - a personalised oncologic approach to treatment of patients with advanced metastatic neuroendocrine neoplasms. Int J Med Sci 2021;18:2166-75. [PMID: 33859524 DOI: 10.7150/ijms.51740] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
20 Malczewska A, Oberg K, Kos-Kudla B. NETest is superior to chromogranin A in neuroendocrine neoplasia: a prospective ENETS CoE analysis. Endocr Connect 2021;10:110-23. [PMID: 33289691 DOI: 10.1530/EC-20-0417] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
21 Liberini V, Huellner MW, Grimaldi S, Finessi M, Thuillier P, Muni A, Pellerito RE, Papotti MG, Piovesan A, Arvat E, Deandreis D. The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future. Diagnostics (Basel) 2020;10:E1083. [PMID: 33322819 DOI: 10.3390/diagnostics10121083] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
22 Levy S, van Veenendaal LM, Korse CM, Breekveldt ECH, Verbeek WHM, Vriens MR, Kuhlmann KFD, van den Berg JG, Valk GD, Tesselaar MET. Survival in Patients with Neuroendocrine Tumours of the Small Intestine: Nomogram Validation and Predictors of Survival. J Clin Med 2020;9:E2502. [PMID: 32756529 DOI: 10.3390/jcm9082502] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
23 Malczewska A, Procner A, Walter A, Kusnierz K, Zajecki W, Aslanian H, Kos-Kudla B. The NETest liquid biopsy is diagnostic for gastric neuroendocrine tumors: observations on the blood-based identification of microscopic and macroscopic residual diseaseOK. BMC Gastroenterol 2020;20:235. [PMID: 32703157 DOI: 10.1186/s12876-020-01348-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
24 Bocchini M, Nicolini F, Severi S, Bongiovanni A, Ibrahim T, Simonetti G, Grassi I, Mazza M. Biomarkers for Pancreatic Neuroendocrine Neoplasms (PanNENs) Management-An Updated Review. Front Oncol 2020;10:831. [PMID: 32537434 DOI: 10.3389/fonc.2020.00831] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
25 Laskaratos FM, Liu M, Malczewska A, Ogunbiyi O, Watkins J, Luong TV, Mandair D, Caplin M, Toumpanakis C. Evaluation of circulating transcript analysis (NETest) in small intestinal neuroendocrine neoplasms after surgical resection. Endocrine 2020;69:430-40. [PMID: 32291735 DOI: 10.1007/s12020-020-02289-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
26 Partelli S, Andreasi V, Muffatti F, Schiavo Lena M, Falconi M. Circulating Neuroendocrine Gene Transcripts (NETest): A Postoperative Strategy for Early Identification of the Efficacy of Radical Surgery for Pancreatic Neuroendocrine Tumors. Ann Surg Oncol 2020;27:3928-36. [PMID: 32253675 DOI: 10.1245/s10434-020-08425-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 17] [Article Influence: 5.5] [Reference Citation Analysis]
27 Malczewska A, Kos-Kudła B, Kidd M, Drozdov I, Bodei L, Matar S, Oberg K, Modlin IM. The clinical applications of a multigene liquid biopsy (NETest) in neuroendocrine tumors. Adv Med Sci 2020;65:18-29. [PMID: 31841822 DOI: 10.1016/j.advms.2019.10.002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 12.5] [Reference Citation Analysis]
28 Öberg K, Califano A, Strosberg J, Ma S, Pape U, Bodei L, Kaltsas G, Toumpanakis C, Goldenring J, Frilling A, Paulson S. A meta-analysis of the accuracy of a neuroendocrine tumor mRNA genomic biomarker (NETest) in blood. Annals of Oncology 2020;31:202-12. [DOI: 10.1016/j.annonc.2019.11.003] [Cited by in Crossref: 50] [Cited by in F6Publishing: 41] [Article Influence: 25.0] [Reference Citation Analysis]
29 Bodei L, Kidd MS, Singh A, van der Zwan WA, Severi S, Drozdov IA, Malczewska A, Baum RP, Kwekkeboom DJ, Paganelli G, Krenning EP, Modlin IM. PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest. Eur J Nucl Med Mol Imaging 2020;47:895-906. [PMID: 31838581 DOI: 10.1007/s00259-019-04601-3] [Cited by in Crossref: 48] [Cited by in F6Publishing: 53] [Article Influence: 16.0] [Reference Citation Analysis]
30 Lee L, Ito T, Jensen RT. Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies. Expert Rev Anticancer Ther. 2019;19:1029-1050. [PMID: 31738624 DOI: 10.1080/14737140.2019.1693893] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 10.0] [Reference Citation Analysis]
31 Rindi G, Wiedenmann B. Neuroendocrine neoplasia goes molecular - time for a change. Nat Rev Clin Oncol 2019;16:149-50. [PMID: 30390038 DOI: 10.1038/s41571-018-0118-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
32 Kidd M, Drozdov IA, Matar S, Gurunlian N, Ferranti NJ, Malczewska A, Bennett P, Bodei L, Modlin IM. Utility of a ready-to-use PCR system for neuroendocrine tumor diagnosis. PLoS One 2019;14:e0218592. [PMID: 31247038 DOI: 10.1371/journal.pone.0218592] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
33 Rindi G, Wiedenmann B. Reply to ‘Time for a change and to adopt a novel molecular genomic approach in NETs’. Nat Rev Clin Oncol 2019;16:270-270. [DOI: 10.1038/s41571-019-0186-4] [Reference Citation Analysis]
34 Malczewska A, Witkowska M, Makulik K, Bocian A, Walter A, Pilch-Kowalczyk J, Zajęcki W, Bodei L, Oberg KE, Kos-Kudła B. NETest liquid biopsy is diagnostic of small intestine and pancreatic neuroendocrine tumors and correlates with imaging. Endocr Connect 2019:EC-19-0030. [PMID: 30865931 DOI: 10.1530/EC-19-0030] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 8.0] [Reference Citation Analysis]
35 Bodei L, Liu E, Paulson S, Gulati A, Freudman J, Grosh W, Kafer S, Wickremesinghe PC, Salem RR. Time for a change and to adopt a novel molecular genomic approach in NETs. Nat Rev Clin Oncol 2019;16:269-70. [PMID: 30809030 DOI: 10.1038/s41571-019-0185-5] [Reference Citation Analysis]
36 Malczewska A, Oberg K, Bodei L, Aslanian H, Lewczuk A, Filosso PL, Wójcik-Giertuga M, Rydel M, Zielińska-Leś I, Walter A, Suarez AL, Kolasińska-Ćwikła A, Roffinella M, Jamidar P, Ziora D, Czyżewski D, Kos-Kudła B, Ćwikła J. NETest Liquid Biopsy Is Diagnostic of Lung Neuroendocrine Tumors and Identifies Progressive Disease. Neuroendocrinology 2019;108:219-31. [PMID: 30654372 DOI: 10.1159/000497037] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]